Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

Previous studies have suggested that, in patients with AL amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation (HDM/SCT), the greatest benefit is seen in those patients achieving a hematologic complete response (CR). We analyzed a series of 421 consecutive patients t...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Cibeira, Maria Teresa, Sanchorawala, Vaishali, Seldin, David C., Quillen, Karen, Berk, John L., Dember, Laura M., Segal, Adam, Ruberg, Frederick, Meier-Ewert, Hans, Andrea, Nancy T., Sloan, J. Mark, Finn, Kathleen T., Doros, Gheorghe, Blade, Joan, Skinner, Martha
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2011
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3204906/
https://ncbi.nlm.nih.gov/pubmed/21828140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-01-330738
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items